Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
0 |
-0.47 |
N/A |
N/A |
2024-04-01 |
2023-12 |
0 |
-0.17 |
N/A |
N/A |
2023-11-09 |
2023-09 |
-1.43 |
-1.14 |
0.29 |
20.28% |
2023-08-10 |
2023-06 |
0 |
-1.47 |
N/A |
N/A |
2023-05-11 |
2023-03 |
0 |
-3.15 |
N/A |
N/A |
2023-03-28 |
2022-12 |
0 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-08-15 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2019-04-21 |
BARRETT JOHN A |
Officer |
222.99K |
Stock Award(Grant) |
2024-02-25 |
BITTERMAN ROBERT J |
Chief Executive Officer |
18.99K |
Purchase |
2023-02-16 |
BRADFORD PATRICIA A |
Director |
3.17K |
Stock Award(Grant) |
2023-02-16 |
CAUWENBERGH GEERT |
Director |
4.24K |
Stock Award(Grant) |
2022-02-14 |
DISPERSYN GERRIT |
Chief Executive Officer |
221.28K |
Stock Award(Grant) |
2022-02-14 |
DORMAN H PAUL |
Director |
20.37K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Sabby Management, LLC |
156.75K |
449.88K |
7.06% |
2023-06-29 |
Vanguard Group Inc |
24.38K |
69.97K |
1.10% |
2023-06-29 |
Bridgeway Capital Management, Inc. |
23.49K |
67.40K |
1.06% |
2023-06-29 |
Anson Funds Management LP |
22.57K |
64.78K |
1.02% |
2023-06-29 |
Cambridge Investment Research Advisors Inc. |
14.23K |
40.85K |
0.64% |
2023-06-29 |
Renaissance Technologies, LLC |
11.28K |
32.37K |
0.51% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Extended Market Index Fund |
24.38K |
69.97K |
1.10% |
2023-06-29 |
Bridgeway Funds Inc-Ultra Small Company Fund |
23.49K |
67.40K |
1.06% |
2023-05-30 |
Fidelity Extended Market Index Fund |
5.43K |
19.01K |
0.24% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
2.86K |
10.00K |
0.13% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
463.00 |
1.62K |
0.02% |
Split |
Date |
1 : 12 |
2023-01-26 |
1 : 55 |
2020-01-15 |
1 : 10 |
2018-01-08 |
1 : 10 |
2016-04-18 |
0.03333 : 1 |
2013-07-24 |